By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kite Pharma, Inc. 

2225 Colorado Avenue

Santa Monica  California  90404  U.S.A.
Phone: 301-824-9999 Fax: n/a


Company News
Kite Pharma, Inc. (KITE) Announces Expanded Agreement With Tel Aviv Sourasky Medical Center And Pioneering Researcher Professor Zelig Eshhar To Develop Novel Chimeric Antigen Receptor (CAR) Approaches For Cancer Immunotherapy 1/22/2015 8:30:27 AM
Kite Pharma, Inc. (KITE) Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process 1/20/2015 7:20:45 AM
SoCal's Kite Pharma, Inc. (KITE) Talks With Insurers to Avoid Gilead Sciences, Inc. (GILD) Price War 1/15/2015 4:15:18 PM
Kite Pharma, Inc. (KITE) Expands Senior Management Team With Appointment Of Claudine Prowse, Ph.D., As SVP, Corporate Communications And Investor Relations 1/9/2015 7:36:48 AM
Kite Pharma, Inc. (KITE) Announces Addition Of Scott N. Bernstein As Vice President Of Intellectual Property Law 1/9/2015 7:30:21 AM
Kite Pharma, Inc. (KITE) Announces Exclusive License With The NIH For T Cell Receptor (TCR)-Based Products To Treat HPV-Associated Cancers 1/8/2015 7:34:56 AM
Kite Pharma, Inc. (KITE) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/7/2015 10:05:04 AM
Kite Pharma, Inc. (KITE) Granted Orphan Drug Designation In The European Union For KTE-C19, Kite's Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy 1/6/2015 10:49:30 AM
Kite Pharma, Inc. (KITE) Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares 12/30/2014 7:24:10 AM
Kite Pharma, Inc. (KITE) Submits Investigational New Drug Application For Phase 1/2 Trial Of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, For The Treatment Of Refractory Aggressive Non-Hodgkin Lymphoma 12/23/2014 7:29:34 AM